Back
Compare AU
Compare GGBL vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Wealthbuilder Global Geared Complex ETF (GGBL) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
GGBL | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 110 | 68 |
Median incremental investment | $2,004.50 | $669.60 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,676.88 | $2,041.20 |
Average age group | > 35 | > 35 |
Key Summary
GGBL | CURE | |
|---|---|---|
Strategy | GGBL.AX was created on 2025-09-30 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. To provide geared exposure to the returns of a portfolio comprising the worlds largest developed market companies (ex Australia), based on free float-adjusted market capitalisation. There is no assurance or guarantee that the returns of the Fund will meet its investment objective. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Betashares Global Shares ETF (155.67 %) | Apellis Pharmaceuticals Inc (1.80 %) Revolution Medicines Inc Ordinary Shares (1.51 %) Madrigal Pharmaceuticals Inc (1.35 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (72.60 %) Japan (6.38 %) United Kingdom of Great Britain and Northern Ireland (3.60 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0 % | 0.45 % |
Key Summary
GGBL | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0 % | 0.45 % |
Price | $24.35 | $64.83 |
Size | N/A | $40.570 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.37 % | 5.08 % |
Market | ASX | ASX |
First listed date | 29/09/2025 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
GGBL | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 110 | 68 |
Median incremental investment | $2,004.50 | $669.60 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,676.88 | $2,041.20 |
Average age group | > 35 | > 35 |
Pros and Cons
GGBL | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
GGBL | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |